Skip to main content

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

Active, not recruiting · Phase 3 · NCT05100862

Conditions: Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma

At a glance

Research payments reported, 2025
$7.7M
U.S. investigators named
48
Sites paid
60
Planned or actual enrollment
799

About the trial

Sponsor
BeOne Medicines
Tested
Zanubrutinib (drug), Rituximab (drug), Lenalidomide (drug), Obinutuzumab (drug)
Dates
Started 2022-03-10; completion 2030-06
Results posted
Not yet

The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R\^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free survival as determined by an independent review committee in accordance with the 2014 modification of the International Working Group on non-Hodgkin lymphoma (NHL) Criteria based on n positron emission tomography and computed tomography (PET/CT), and to compare the efficacy of zanubrutinib plus rituximab versus R\^2 in participants with R/R marginal zone lymphoma (MZL), as measured by progression free survival (PFS) assessed by IRC in accordance with CT-based …

From ClinicalTrials.gov, last updated 2026-10-15. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Beigene, Ltd. reported $7.7M in research payments for this study in 2025 (789 payments).

Products named: Brukinsa

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.